by Randy E. Miller | Jun 27, 2024 | FDA, FOIA, SEC
FOIAengine Reveals Trends Behind the Big Numbers at FDA, SEC This week we analyze the sources of Freedom of Information Act requests made during May to the Food and Drug Administration and the Securities and Exchange Commission. This analysis provides a macro view...
by Randy E. Miller | May 30, 2024 | FDA, FOIA, Hedge Funds, News Media, Pharmaceuticals, Stock Market
FOIAengine: Requests Show FDA Still Under Pressure This week, we’re taking a closer look at the numerous Freedom of Information Act requests recently filed with the Food and Drug Administration concerning the problematic India pharmaceutical industry. As we noted in...
by Randy E. Miller | Apr 24, 2024 | FDA, FOIA, News Media, SEC
FOIAengine: Insights From the Latest FDA and SEC Requests News media outlets are among the most prolific submitters of FOIA requests to federal agencies. These requests signal – in real time – the stories that journalists are researching and writing. To illustrate...
by Randy E. Miller | Mar 27, 2024 | FDA, FOIA, Hedge Funds, Law Firms, Litigation, Non-Profits, Pharmaceuticals, Politics, Short-Selling, Stock Market
FOIAengine: Conservative Activists, Law Firms, Non-Profits Signal Competing Agendas A review of the most recent Freedom of Information Act requests made to the Food and Drug Administration illustrates how political organizations, law firms, news media, and financial...
by Randy E. Miller | Feb 14, 2024 | FDA, FOIA, Hedge Funds, Litigation, Pharmaceuticals, Short-Selling, Stock Market
FOIAengine Breaks Down the Action Financial firms are continuing to monitor many of the pharmaceutical manufacturers we’ve reported on in recent months, including Krystal Biotech, Apellis Pharmaceuticals, Establishment Labs, Catalent and Astellas. That’s according to...
